JP7550142B2 - 関節リウマチ治療のためのバイオマーカー - Google Patents

関節リウマチ治療のためのバイオマーカー Download PDF

Info

Publication number
JP7550142B2
JP7550142B2 JP2021516097A JP2021516097A JP7550142B2 JP 7550142 B2 JP7550142 B2 JP 7550142B2 JP 2021516097 A JP2021516097 A JP 2021516097A JP 2021516097 A JP2021516097 A JP 2021516097A JP 7550142 B2 JP7550142 B2 JP 7550142B2
Authority
JP
Japan
Prior art keywords
rheumatoid arthritis
weeks
drug
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516097A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020218232A1 (https=
JPWO2020218232A5 (https=
Inventor
信之 安田
知広 山田
文利 田胡
誠一郎 北条
俊夫 今井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2020218232A1 publication Critical patent/JPWO2020218232A1/ja
Publication of JPWO2020218232A5 publication Critical patent/JPWO2020218232A5/ja
Application granted granted Critical
Publication of JP7550142B2 publication Critical patent/JP7550142B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Virology (AREA)
JP2021516097A 2019-04-23 2020-04-20 関節リウマチ治療のためのバイオマーカー Active JP7550142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019081452 2019-04-23
JP2019081452 2019-04-23
PCT/JP2020/017016 WO2020218232A1 (ja) 2019-04-23 2020-04-20 関節リウマチ治療のためのバイオマーカー

Publications (3)

Publication Number Publication Date
JPWO2020218232A1 JPWO2020218232A1 (https=) 2020-10-29
JPWO2020218232A5 JPWO2020218232A5 (https=) 2023-04-10
JP7550142B2 true JP7550142B2 (ja) 2024-09-12

Family

ID=72942731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516097A Active JP7550142B2 (ja) 2019-04-23 2020-04-20 関節リウマチ治療のためのバイオマーカー

Country Status (5)

Country Link
US (1) US20220205980A1 (https=)
EP (1) EP3960198A4 (https=)
JP (1) JP7550142B2 (https=)
CN (1) CN113710272A (https=)
WO (1) WO2020218232A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022092183A1 (ja) * 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017193541A (ja) 2016-04-19 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263391B2 (ja) 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
ES2751549T3 (es) * 2009-11-30 2020-04-01 Janssen Biotech Inc Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017193541A (ja) 2016-04-19 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chara et al.，Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis，Arthritis Research & Therapy， 14:R175，2012年，http://arthritis-research.com/content/14/4/R175
Imai and Yasuda，Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway，Inflammation and Regeneration，36:9，2016年，DOI 10.1186/s41232-016-0017-2
TANAKA, Y. et al.，Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheum，Arthritis & Rheumatology，2019年10月，Vol.71/No.Suppl. 10，pp.0932
YANO, R. et al.，Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheuma，Acta Medica Okayama，2007年04月，Vol.61/No.2，pp.89-98
自社創製の抗フラクタルカイン抗体 E6011 について、臨床I/II相試験結果を発表―関節リウマチおよびクローン病に対する安全性と忍容性および臨床活性を示唆する結果を取得―，News Release エーザイ株式会社，2016年06月13日，https://www.eisai.co.jp/news/news201640.html

Also Published As

Publication number Publication date
JPWO2020218232A1 (https=) 2020-10-29
WO2020218232A1 (ja) 2020-10-29
US20220205980A1 (en) 2022-06-30
EP3960198A4 (en) 2023-01-11
CN113710272A (zh) 2021-11-26
EP3960198A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
SG187945A1 (en) Anti-ox40 antibodies and methods of using the same
TWI747043B (zh) Btla同效劑抗體及其用途
CN106687133A (zh) 使用针对cd40l的域抗体治疗自身免疫性疾病的方法
EP2425250B1 (en) Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP7550142B2 (ja) 関節リウマチ治療のためのバイオマーカー
JP2018065796A (ja) クローン病を治療するための医薬組成物
US20140234307A1 (en) Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20110053209A1 (en) Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP2019507102A (ja) 抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用
WO2020178193A1 (en) Method of treatment of sarcoidosis
EP3211007B1 (en) Pharmaceutical composition for treating crohn's disease
AU2014259523B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
EP3159007A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
EP4052727A1 (en) Immune response suppressor
KR20240139085A (ko) 치료 항체
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240902

R150 Certificate of patent or registration of utility model

Ref document number: 7550142

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150